Answers are grounded in this paper and cite their sources.
Orforglipron is a promising treatment option for T2DM and overweight or obesity, in terms of glucose control and weight loss. The increased frequency of adverse events, particularly in those receiving high doses and after rapid-dose escalation, requires caution before widespread use.
No takes yet. Share an insight, caveat, or question.
Gouveri et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: